Matthijs Vynck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthijs Vynck has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Olivier Thas
Data Science Institute, I-BioStat, Hasselt University, Hasselt, Belgium
13 shared publications - Jo Vandesompele
Cancer Research Institute Ghent, Ghent, Belgium
10 shared publications - Ward De Spiegelaere
Cancer Research Institute Ghent (CRIG), Medical Research Building, University Hospital Ghent, Ghent, Belgium
8 shared publications - Lynn Vanhaecke
Laboratory of Integrative Metabolomics, Department of Translational Physiology, Infectiology and Public Health, Ghent University, Ghent, Belgium
5 shared publications Ellen De Paepe
Laboratory of Integrative Metabolomics (LIMET), Department of Translational Physiology, Infectiology and Public Health, Faculty of Veterinary Medicine, Salisburylaan 133, Merelbeke 9820, Belgium
4 shared publicationsFriedel Nollet
Department of Laboratory Medicine AZ Sint‐Jan Hospital Bruges Belgium
4 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
A validated dual-extraction approach for comprehensive ultra-high performance liquid chromatography-high resolution mass spectrometry-based metabolomics and lipidomics of human placenta applied to the ENVIRONAGE birth cohort
The placenta is the interface between maternal exposome and fetal development. However, analytical platforms for simultaneous analysis of its (semi-)polar metabolome and lipidome from a single tissue aliquot are lacking. We developed and validated a dual-extraction method for metabolomics and lipidomics analyses of human placenta.,A Design of Experiments approach was based on 54 targeted metabolites and lipids (log P=–3.24-10.59) and untargeted feature count to optimize bead mill homogenization, solvent composition and dilution for sequential extraction, prior to ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry. Method validation was performed on pooled porcine (as a proxy) and human placenta samples. Targeted validation demonstrated a coefficient of variation (CV) ≤20% for repeatability and inter-day precision and a coefficient of determination (R²) ≥0.99 for >26/27 metabolites and >17/27 lipids. Untargeted analysis consistently detected 2,811 and 5,412 features (CV ≤30%) in metabolite and lipid fractions, respectively.,The method was applied to 371 placental samples from the ENVIRONAGE birth cohort to assess metabolic perturbations associated with maternal lifestyle factors and adverse neonatal outcomes (small for gestational age (SGA) status, preterm birth, and low 1-minute Appearance, Pulse, Grimace, Activity and Respiration (APGAR)). Notably, placental cotinine levels showed associations with self-reported maternal smoking behavior (η² =0.14, FDR p <0.2). Pathway enrichment and targeted analyses identified outcome-specific metabolic signatures under basic covariate adjustment, though these were sensitive to extended covariate correction.,Our validated dual-extraction platform enables reproducible, resource-efficient placental phenotyping with demonstrated sensitivity to exposome signals, supporting large-scale birth cohort research into adverse neonatal outcomes.
- 10 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA validated dual-extraction approach for comprehensive ultra-high performance liquid chromatography-high resolution mass spectrometry-based metabolomics and lipidomics of human placenta applied to the ENVIRONAGE birth cohort
The placenta is the interface between maternal exposome and fetal development. However, analytical platforms for simultaneous analysis of its (semi-)polar metabolome and lipidome from a single tissue aliquot are lacking. We developed and validated a dual-extraction method for metabolomics and lipidomics analyses of human placenta.,A Design of Experiments approach was based on 54 targeted metabolites and lipids (log P=–3.24-10.59) and untargeted feature count to optimize bead mill homogenization, solvent composition and dilution for sequential extraction, prior to ultra-high performance liquid chromatography coupled to high-resolution mass spectrometry. Method validation was performed on pooled porcine (as a proxy) and human placenta samples. Targeted validation demonstrated a coefficient of variation (CV) ≤20% for repeatability and inter-day precision and a coefficient of determination (R²) ≥0.99 for >26/27 metabolites and >17/27 lipids. Untargeted analysis consistently detected 2,811 and 5,412 features (CV ≤30%) in metabolite and lipid fractions, respectively.,The method was applied to 371 placental samples from the ENVIRONAGE birth cohort to assess metabolic perturbations associated with maternal lifestyle factors and adverse neonatal outcomes (small for gestational age (SGA) status, preterm birth, and low 1-minute Appearance, Pulse, Grimace, Activity and Respiration (APGAR)). Notably, placental cotinine levels showed associations with self-reported maternal smoking behavior (η² =0.14, FDR p <0.2). Pathway enrichment and targeted analyses identified outcome-specific metabolic signatures under basic covariate adjustment, though these were sensitive to extended covariate correction.,Our validated dual-extraction platform enables reproducible, resource-efficient placental phenotyping with demonstrated sensitivity to exposome signals, supporting large-scale birth cohort research into adverse neonatal outcomes.
- Open Access
- 11 June 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (24) , 17627-17637
Robust Metabolomics Data Normalization across Scales and Experimental Designs
Metabolomics studies employing liquid chromatography-mass spectrometry are affected by signal drift and batch effects, introducing technical variance that impedes biological knowledge discovery. Quality control (QC) sample-based normalization strategies are widely implemented but remain vulnerable to outliers, thereby reducing normalization performance. We introduce rLOESS, rGAM, and tGAM, three robust normalization methods that improve resistance to outliers by downweighting or accommodating them. Leveraging additive models, the rGAM and tGAM methods allow flexible nonlinear modeling, differential sample weighting, and data-driven QC representativeness evaluation. Implementations of these methods are gathered in the Metanorm R package, integrating robust normalization with visualization for performance verification while supporting efficient parallel processing. In in silico and/or experimental data sets, the robust methods, relative to several popular existing strategies, improved replicate concordance and reduced drift and batch effects. The robust methods, with improved recovery of the underlying signal demonstrated in simulation, produced distinct differential abundance results, highlighting the impact of normalization on downstream statistical inference. Overall, tGAM-based normalization suggested the best performance across scenarios and is proposed as the default choice. Metanorm is versatile, supporting normalization in metabolomics studies across scales and experimental setups. Metanorm is freely available at https://github.com/UGent-LIMET/Metanorm.
- 11 June 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (24) , 17627-17637
Open AccessRobust Metabolomics Data Normalization across Scales and Experimental Designs
Metabolomics studies employing liquid chromatography-mass spectrometry are affected by signal drift and batch effects, introducing technical variance that impedes biological knowledge discovery. Quality control (QC) sample-based normalization strategies are widely implemented but remain vulnerable to outliers, thereby reducing normalization performance. We introduce rLOESS, rGAM, and tGAM, three robust normalization methods that improve resistance to outliers by downweighting or accommodating them. Leveraging additive models, the rGAM and tGAM methods allow flexible nonlinear modeling, differential sample weighting, and data-driven QC representativeness evaluation. Implementations of these methods are gathered in the Metanorm R package, integrating robust normalization with visualization for performance verification while supporting efficient parallel processing. In in silico and/or experimental data sets, the robust methods, relative to several popular existing strategies, improved replicate concordance and reduced drift and batch effects. The robust methods, with improved recovery of the underlying signal demonstrated in simulation, produced distinct differential abundance results, highlighting the impact of normalization on downstream statistical inference. Overall, tGAM-based normalization suggested the best performance across scenarios and is proposed as the default choice. Metanorm is versatile, supporting normalization in metabolomics studies across scales and experimental setups. Metanorm is freely available at https://github.com/UGent-LIMET/Metanorm.
- Open Access
- 16 March 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (12) , 8947-8955
Challenges and Good Practices in Preprocessing and Normalization of Untargeted DNA Adductomics Data in Exposomics Research
DNA adductomics is the study of the whole of DNA adducts in a biological sample and is a valuable asset to exposomics research. To date, a clear view on how to analyze larger sample series is lacking in DNA adductomics, and the preprocessing of untargeted DNA adductomics data is seldom applied. This work aimed to optimize a DNA adductomics data preprocessing workflow (in true untargeted mode). Building upon the xcms R package, we optimized parameters for peak detection, retention time alignment, and peak grouping to reliably detect and integrate putative DNA adduct LC-MS peaks. Next, to ensure reliable downstream data analysis, six sample- and feature-based normalization methods were tested and quantitatively evaluated in two data sets (placental tissue, n = 375, and blood samples, n = 51). As a result, a successful and reproducible procedure for optimization of xcms parameters for DNA adductomics is proposed. Furthermore, evaluation of normalization methods demonstrated the importance and limitations of objective (RSD* and D-ratio) and subjective, i.e., visual (PCA score plot) evaluation. This work supports reproducible and transparent untargeted DNA adductomics data preprocessing to be implemented in large-scale exposomics studies.
- 16 March 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (12) , 8947-8955
Open AccessChallenges and Good Practices in Preprocessing and Normalization of Untargeted DNA Adductomics Data in Exposomics Research
DNA adductomics is the study of the whole of DNA adducts in a biological sample and is a valuable asset to exposomics research. To date, a clear view on how to analyze larger sample series is lacking in DNA adductomics, and the preprocessing of untargeted DNA adductomics data is seldom applied. This work aimed to optimize a DNA adductomics data preprocessing workflow (in true untargeted mode). Building upon the xcms R package, we optimized parameters for peak detection, retention time alignment, and peak grouping to reliably detect and integrate putative DNA adduct LC-MS peaks. Next, to ensure reliable downstream data analysis, six sample- and feature-based normalization methods were tested and quantitatively evaluated in two data sets (placental tissue, n = 375, and blood samples, n = 51). As a result, a successful and reproducible procedure for optimization of xcms parameters for DNA adductomics is proposed. Furthermore, evaluation of normalization methods demonstrated the importance and limitations of objective (RSD* and D-ratio) and subjective, i.e., visual (PCA score plot) evaluation. This work supports reproducible and transparent untargeted DNA adductomics data preprocessing to be implemented in large-scale exposomics studies.
- 13 February 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (3) , 837-850
Validation and clinical study of single-step vitrification combined with single-step warming of human blastocysts
This study assesses the feasibility of single-step vitrification and warming (SSV/SSW) for human blastocysts. Previous animal study models have shown possi
- 13 February 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (3) , 837-850
Validation and clinical study of single-step vitrification combined with single-step warming of human blastocysts
This study assesses the feasibility of single-step vitrification and warming (SSV/SSW) for human blastocysts. Previous animal study models have shown possi
- 7 February 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1394, 345210
Standardized digital PCR assay validation using PCR-ValiPal, demonstrated in cross-platform quantification of bovine papilloma virus
- 7 February 2026
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1394, 345210
Standardized digital PCR assay validation using PCR-ValiPal, demonstrated in cross-platform quantification of bovine papilloma virus
- Open Access
- 13 November 2025
- Published by Elsevier in EBioMedicine
- Vol. 122, 106019
A repository of the salivary metabolome and its key drivers in 1436 European children
- 13 November 2025
- Published by Elsevier in EBioMedicine
- Vol. 122, 106019
Open AccessA repository of the salivary metabolome and its key drivers in 1436 European children
- Open Access
Robust metabolomics data normalization across scales and experimental designs
Metabolomics studies employing liquid chromatography-mass spectrometry are affected by signal drift and batch effects, introducing technical variance that impedes biological knowledge discovery. Quality control (QC) sample-based normalization strategies are widely implemented but remain vulnerable to outliers, thereby reducing normalization performance. We introduce rLOESS, rGAM and tGAM, three robust normalization methods that improve resistance to outliers by downweighting or accommodating them. Leveraging additive models, the rGAM and tGAM methods allow flexible non-linear modeling, differential sample weighting, and data-driven QC representativeness evaluation. Implementations of these methods are gathered in the Metanorm R package, integrating robust normalization with visualization for performance verification, while supporting efficient parallel processing. Spanning in silico and experimental datasets, the robust methods, relative to existing strategies, consistently demonstrated a reduction in false positive and false negative differentially abundant metabolites, improved replicate concordance, and reduced batch effects. Metanorm is versatile, supporting normalization in metabolomics studies across scales and experimental setups.
Open AccessRobust metabolomics data normalization across scales and experimental designs
Metabolomics studies employing liquid chromatography-mass spectrometry are affected by signal drift and batch effects, introducing technical variance that impedes biological knowledge discovery. Quality control (QC) sample-based normalization strategies are widely implemented but remain vulnerable to outliers, thereby reducing normalization performance. We introduce rLOESS, rGAM and tGAM, three robust normalization methods that improve resistance to outliers by downweighting or accommodating them. Leveraging additive models, the rGAM and tGAM methods allow flexible non-linear modeling, differential sample weighting, and data-driven QC representativeness evaluation. Implementations of these methods are gathered in the Metanorm R package, integrating robust normalization with visualization for performance verification, while supporting efficient parallel processing. Spanning in silico and experimental datasets, the robust methods, relative to existing strategies, consistently demonstrated a reduction in false positive and false negative differentially abundant metabolites, improved replicate concordance, and reduced batch effects. Metanorm is versatile, supporting normalization in metabolomics studies across scales and experimental setups.
- Open Access
Cross-platform digital PCR evaluation of bovine papilloma virus quantification: introducing PCR-ValiPal for Standardized guided assay validation
Digital Polymerase chain reaction (dPCR) enables precise and absolute quantification of nucleic acids by partitioning samples into thousands of individual PCR micro-reactions. While it minimizes the need for standard curves and enhances reproducibility compared to qPCR, thorough assay validation remains crucial. We introduce PCR-ValiPal, a user-friendly web application that standardizes dPCR assay validation steps and streamlines calculations of limit of blank (LOB), limit of detection (LOD), limit of quantification (LOQ), precision, trueness, and linearity in accordance with International Organization for Standardization (ISO) 20395:2019. To demonstrate PCR-ValiPal’s capabilities and the value of method-specific optimization, we use it to validate a novel three-color PCR assay for Bovine Papillomavirus (BPV) types 1 and 2, comparing four platforms: Naica (droplet dPCR), QIAcuity (microwell dPCR), LOAA (real-time dPCR), and CFX96 (qPCR). Using synthetic standards, we assess the platforms’ performance under identical assay conditions. Naica and QIAcuity showed lower LOB and LOQ values, along with minimal bias for BPV-1, while LOAA demonstrated stable but negative bias. Although qPCR exhibited the highest sensitivity for BPV-2, it was less sensitive at low concentrations for BPV-1. These results underscore the value of method-specific optimization and the usefulness of PCR-ValiPal.
Open AccessCross-platform digital PCR evaluation of bovine papilloma virus quantification: introducing PCR-ValiPal for Standardized guided assay validation
Digital Polymerase chain reaction (dPCR) enables precise and absolute quantification of nucleic acids by partitioning samples into thousands of individual PCR micro-reactions. While it minimizes the need for standard curves and enhances reproducibility compared to qPCR, thorough assay validation remains crucial. We introduce PCR-ValiPal, a user-friendly web application that standardizes dPCR assay validation steps and streamlines calculations of limit of blank (LOB), limit of detection (LOD), limit of quantification (LOQ), precision, trueness, and linearity in accordance with International Organization for Standardization (ISO) 20395:2019. To demonstrate PCR-ValiPal’s capabilities and the value of method-specific optimization, we use it to validate a novel three-color PCR assay for Bovine Papillomavirus (BPV) types 1 and 2, comparing four platforms: Naica (droplet dPCR), QIAcuity (microwell dPCR), LOAA (real-time dPCR), and CFX96 (qPCR). Using synthetic standards, we assess the platforms’ performance under identical assay conditions. Naica and QIAcuity showed lower LOB and LOQ values, along with minimal bias for BPV-1, while LOAA demonstrated stable but negative bias. Although qPCR exhibited the highest sensitivity for BPV-2, it was less sensitive at low concentrations for BPV-1. These results underscore the value of method-specific optimization and the usefulness of PCR-ValiPal.
- Open Access
- 29 April 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (18) , 9927-9934
Automated Integration and Quality Assessment of Chromatographic Peaks in LC–MS-Based Metabolomics and Lipidomics Using TARDIS
In recent years, liquid chromatography coupled to mass spectrometry (LC-MS) has emerged as the main technology to measure the whole of small molecules (the metabolome) in a diversity of matrices. Within the field of computational metabolomics, significant efforts have been made in the development of tools to (pre)process untargeted LC-MS data. However, tools that circumvent the time-consuming, manual preprocessing of targeted LC-MS data with vendor-specific software remain sparse. We therefore present TARDIS, an open-source R package for the analysis of targeted LC-MS metabolomics and lipidomics data. Both established (area under the curve, maximum intensity and points over the peak) and recently developed (custom signal-to-noise ratio and bell-curve similarity) quality metrics were included to offer increased efficiency of peak quality evaluation. The robustness of TARDIS' peak integration was demonstrated through a quantitative comparison to state-of-the-art vendor software. To this end, applicability at a large scale (n = 1786) was validated across three distinct biofluids (stool, saliva and urine) and two LC-MS instruments, using data from the FAME, ENVIRONAGE, and FGFP cohort studies. In conclusion, TARDIS offers a robust and scalable open-source solution for the targeted analysis of LC-MS metabolomics and lipidomics data. TARDIS and its source code are freely available at https://github.com/UGent-LIMET/TARDIS.
- 29 April 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (18) , 9927-9934
Open AccessAutomated Integration and Quality Assessment of Chromatographic Peaks in LC–MS-Based Metabolomics and Lipidomics Using TARDIS
In recent years, liquid chromatography coupled to mass spectrometry (LC-MS) has emerged as the main technology to measure the whole of small molecules (the metabolome) in a diversity of matrices. Within the field of computational metabolomics, significant efforts have been made in the development of tools to (pre)process untargeted LC-MS data. However, tools that circumvent the time-consuming, manual preprocessing of targeted LC-MS data with vendor-specific software remain sparse. We therefore present TARDIS, an open-source R package for the analysis of targeted LC-MS metabolomics and lipidomics data. Both established (area under the curve, maximum intensity and points over the peak) and recently developed (custom signal-to-noise ratio and bell-curve similarity) quality metrics were included to offer increased efficiency of peak quality evaluation. The robustness of TARDIS' peak integration was demonstrated through a quantitative comparison to state-of-the-art vendor software. To this end, applicability at a large scale (n = 1786) was validated across three distinct biofluids (stool, saliva and urine) and two LC-MS instruments, using data from the FAME, ENVIRONAGE, and FGFP cohort studies. In conclusion, TARDIS offers a robust and scalable open-source solution for the targeted analysis of LC-MS metabolomics and lipidomics data. TARDIS and its source code are freely available at https://github.com/UGent-LIMET/TARDIS.
- 3 April 2025
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 23 (2) , 267-277
The Poly (ADP‐Ribose) Polymerase‐1 Enzyme Is Overexpressed in Various Solid Canine Tumours: An Immunohistochemical Study
The enzyme poly (ADP‐ribose) polymerase‐1 (PARP‐1) is crucial for cellular regulation and DNA repair. Its immunohistochemical overexpression is known in various human neoplasms, but it was not yet a topic of veterinary research. Formalin‐fixed paraffin‐embedded canine samples of 15 controls and 34 tumours were immunohistochemically tested for PARP‐1 expression. Controls included five skin samples with mast cells, five oral mucosa samples and five thyroid glands. Tumours included 18 mast cell tumours (MCTs), 10 oral squamous cell carcinomas (SCCs) and six follicular thyroid carcinomas. A board‐certified veterinary pathologist defined the optimal region for the blind PARP‐1 evaluation, assessed by two independent veterinary PhD students. Positive nuclei were evaluated by the immunoreactivity score (IRS) and quick score (QS) and, for both scores, the averages of the two observers were used for statistical analysis. In all MCTs, 6/10 SCCs and all thyroid carcinomas as well as four thyroid controls a nuclear expression was observed. A cytoplasmic granular staining was visible in all dermal mast cells and in 11/18 MCTs due to non‐specific antibody uptake. No PARP‐1 was expressed in 11/15 controls.Compared to the controls, thyroid carcinomas significantly overexpressed PARP‐1 when calculated by IRS and QS (p = 0.003 and p = 0.005, respectively). The latter also applied to the MCTs (p = 0.001). A significantly higher PARP‐1 IRS and QS were observed in thyroid carcinomas (p = 0.003, p = 0.005) and MCTs (p = 0.003, p = 0.012) compared to oral SCCs. The immunohistochemical PARP‐1 overexpression in these tumours invites further research to assess its potential as a therapeutic target.
- 3 April 2025
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 23 (2) , 267-277
The Poly (ADP‐Ribose) Polymerase‐1 Enzyme Is Overexpressed in Various Solid Canine Tumours: An Immunohistochemical Study
The enzyme poly (ADP‐ribose) polymerase‐1 (PARP‐1) is crucial for cellular regulation and DNA repair. Its immunohistochemical overexpression is known in various human neoplasms, but it was not yet a topic of veterinary research. Formalin‐fixed paraffin‐embedded canine samples of 15 controls and 34 tumours were immunohistochemically tested for PARP‐1 expression. Controls included five skin samples with mast cells, five oral mucosa samples and five thyroid glands. Tumours included 18 mast cell tumours (MCTs), 10 oral squamous cell carcinomas (SCCs) and six follicular thyroid carcinomas. A board‐certified veterinary pathologist defined the optimal region for the blind PARP‐1 evaluation, assessed by two independent veterinary PhD students. Positive nuclei were evaluated by the immunoreactivity score (IRS) and quick score (QS) and, for both scores, the averages of the two observers were used for statistical analysis. In all MCTs, 6/10 SCCs and all thyroid carcinomas as well as four thyroid controls a nuclear expression was observed. A cytoplasmic granular staining was visible in all dermal mast cells and in 11/18 MCTs due to non‐specific antibody uptake. No PARP‐1 was expressed in 11/15 controls.Compared to the controls, thyroid carcinomas significantly overexpressed PARP‐1 when calculated by IRS and QS (p = 0.003 and p = 0.005, respectively). The latter also applied to the MCTs (p = 0.001). A significantly higher PARP‐1 IRS and QS were observed in thyroid carcinomas (p = 0.003, p = 0.005) and MCTs (p = 0.003, p = 0.012) compared to oral SCCs. The immunohistochemical PARP‐1 overexpression in these tumours invites further research to assess its potential as a therapeutic target.